[en] The use of doxorubicin (DOX) chemotherapy is restricted due to dose-dependent cardiotoxicity. Pyridoxamine (PM) is a vitamin B6 derivative with favorable effects on diverse cardiovascular diseases, suggesting a cardioprotective effect on DOX-induced cardiotoxicity. The cardioprotective nature of PM was investigated in a rat model of DOX-induced cardiotoxicity. Six-week-old female Sprague Dawley rats were treated intravenously with 2 mg/kg DOX or saline (CTRL) weekly for eight weeks. Two other groups received PM via the drinking water next to DOX (DOX+PM) or saline (CTRL+PM). Echocardiography, strain analysis, and hemodynamic measurements were performed to evaluate cardiac function. Fibrotic remodeling, myocardial inflammation, oxidative stress, apoptosis, and ferroptosis were evaluated by various in vitro techniques. PM significantly attenuated DOX-induced left ventricular (LV) dilated cardiomyopathy and limited TGF-β1-related LV fibrotic remodeling and macrophage-driven myocardial inflammation. PM protected against DOX-induced ferroptosis, as evidenced by restored DOX-induced disturbance of redox balance, improved cytosolic and mitochondrial iron regulation, and reduced mitochondrial damage at the gene level. In conclusion, PM attenuated the development of cardiac damage after DOX treatment by reducing myocardial fibrosis, inflammation, and mitochondrial damage and by restoring redox and iron regulation at the gene level, suggesting that PM may be a novel cardioprotective strategy for DOX-induced cardiomyopathy.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Haesen, Sibren ; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
Jager, Manon Marie ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires (DMI) ; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
Brillouet, Aline; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
de Laat, Iris; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
Vastmans, Lotte ; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
Verghote, Eline; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
Delaet, Anouk; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
D'Haese, Sarah ; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium ; Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, University of Maastricht, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
Hamad, Ibrahim; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium ; VIB Laboratory of Translational Immunomodulation, VIB Center for Inflammation Research (IRC) Hasselt University, 3590 Diepenbeek, Belgium
Kleinewietfeld, Markus; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium ; VIB Laboratory of Translational Immunomodulation, VIB Center for Inflammation Research (IRC) Hasselt University, 3590 Diepenbeek, Belgium
Mebis, Jeroen; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium ; Department of Medical Oncology, Jessa Hospital, Stadsomvaart 11, 3500 Hasselt, Belgium
Mullens, Wilfried; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium ; Department of Cardiology, Ziekenhuis Oost Limburg, Schiepse Bos 6, 3600 Genk, Belgium
Lambrichts, Ivo ; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
Wolfs, Esther; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
Deluyker, Dorien; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
Bito, Virginie ; UHasselt, Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Agoralaan, 3590 Diepenbeek, Belgium
FWO - Fonds Wetenschappelijk Onderzoek Vlaanderen UHasselt - Hasselt University
Funding text :
This research was funded by the Flemish Fund for Scientific Research (FWO Flanders, Brussels, Belgium) with grant numbers 1196221N and G040220FWO, UHasselt Special Research Fund (BOF19KP07) and Limburg Cancer Foundation.
Ferlay J. Colombet M. Soerjomataram I. Parkin D.M. Pineros M. Znaor A. Bray F. Cancer statistics for the year 2020: An overview Int. J. Cancer 2021 online ahead of print 10.1002/ijc.33588
Cardiovascular Diseases (CVDs) Available online: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed on 9 March 2023)
Miller K.D. Nogueira L. Devasia T. Mariotto A.B. Yabroff K.R. Jemal A. Kramer J. Siegel R.L. Cancer treatment and survivorship statistics, 2022 CA Cancer J. Clin. 2022 72 409 436 10.3322/caac.21731 35736631
McGowan J.V. Chung R. Maulik A. Piotrowska I. Walker J.M. Yellon D.M. Anthracycline Chemotherapy and Cardiotoxicity Cardiovasc. Drugs Ther. 2017 31 63 75 10.1007/s10557-016-6711-0
Lopez-Sendon J. Alvarez-Ortega C. Zamora Aunon P. Buno Soto A. Lyon A.R. Farmakis D. Cardinale D. Canales Albendea M. Feliu Batlle J. Rodriguez Rodriguez I. et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: The CARDIOTOX registry Eur. Heart J. 2020 41 1720 1729 10.1093/eurheartj/ehaa006
Sturgeon K.M. Deng L. Bluethmann S.M. Zhou S. Trifiletti D.M. Jiang C. Kelly S.P. Zaorsky N.G. A population-based study of cardiovascular disease mortality risk in US cancer patients Eur. Heart J. 2019 40 3889 3897 10.1093/eurheartj/ehz766 31761945
Songbo M. Lang H. Xinyong C. Bin X. Ping Z. Liang S. Oxidative stress injury in doxorubicin-induced cardiotoxicity Toxicol. Lett. 2019 307 41 48 10.1016/j.toxlet.2019.02.013
Dixon S.J. Lemberg K.M. Lamprecht M.R. Skouta R. Zaitsev E.M. Gleason C.E. Patel D.N. Bauer A.J. Cantley A.M. Yang W.S. et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death Cell 2012 149 1060 1072 10.1016/j.cell.2012.03.042
Ichikawa Y. Ghanefar M. Bayeva M. Wu R. Khechaduri A. Naga Prasad S.V. Mutharasan R.K. Naik T.J. Ardehali H. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation J. Clin. Investig. 2014 124 617 630 10.1172/JCI72931 24382354
Simunek T. Sterba M. Popelova O. Adamcova M. Hrdina R. Gersl V. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron Pharmacol. Rep. 2009 61 154 171 10.1016/S1734-1140(09)70018-0
Sawicki K.T. De Jesus A. Ardehali H. Iron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets Circ. Res. 2023 132 379 396 10.1161/CIRCRESAHA.122.321667 36730380
Zhang S. Liu X. Bawa-Khalfe T. Lu L.S. Lyu Y.L. Liu L.F. Yeh E.T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat. Med. 2012 18 1639 1642 10.1038/nm.2919 23104132
Lyon A.R. Lopez-Fernandez T. Couch L.S. Asteggiano R. Aznar M.C. Bergler-Klein J. Boriani G. Cardinale D. Cordoba R. Cosyns B. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur. Heart J. 2022 43 4229 4361 10.1093/eurheartj/ehac244
Gulati G. Heck S.L. Ree A.H. Hoffmann P. Schulz-Menger J. Fagerland M.W. Gravdehaug B. von Knobelsdorff-Brenkenhoff F. Bratland A. Storas T.H. et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol Eur. Heart J. 2016 37 1671 1680 10.1093/eurheartj/ehw022
Livi L. Barletta G. Martella F. Saieva C. Desideri I. Bacci C. Del Bene M.R. Airoldi M. Amoroso D. Coltelli L. et al. Cardioprotective Strategy for Patients with Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial JAMA Oncol. 2021 7 1544 1549 10.1001/jamaoncol.2021.3395
Vaduganathan M. Hirji S.A. Qamar A. Bajaj N. Gupta A. Zaha V. Chandra A. Haykowsky M. Ky B. Moslehi J. et al. Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy JACC CardioOncology 2019 1 54 65 10.1016/j.jaccao.2019.08.006
Macedo A.V.S. Hajjar L.A. Lyon A.R. Nascimento B.R. Putzu A. Rossi L. Costa R.B. Landoni G. Nogueira-Rodrigues A. Ribeiro A.L.P. Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer JACC CardioOncology 2019 1 68 79 10.1016/j.jaccao.2019.08.003 34396164
van Dalen E.C. Caron H.N. Dickinson H.O. Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines Cochrane Database Syst. Rev. 2011 2011 CD003917 10.1002/14651858.CD003917.pub4
Swain S.M. Whaley F.S. Gerber M.C. Weisberg S. York M. Spicer D. Jones S.E. Wadler S. Desai A. Vogel C. et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J. Clin. Oncol. 1997 15 1318 1332 10.1200/JCO.1997.15.4.1318
Deluyker D. Ferferieva V. Driesen R.B. Verboven M. Lambrichts I. Bito V. Pyridoxamine improves survival and limits cardiac dysfunction after MI Sci. Rep. 2017 7 16010 10.1038/s41598-017-16255-y
Watson A.M. Soro-Paavonen A. Sheehy K. Li J. Calkin A.C. Koitka A. Rajan S.N. Brasacchio D. Allen T.J. Cooper M.E. et al. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice Diabetologia 2011 54 681 689 10.1007/s00125-010-2000-9
Kumrungsee T. Peipei Z. Yanaka N. Suda T. Kato N. Emerging cardioprotective mechanisms of vitamin B6: A narrative review Eur. J. Nutr. 2022 61 605 613 10.1007/s00394-021-02665-2 34436643
Stach K. Stach W. Augoff K. Vitamin B6 in Health and Disease Nutrients 2021 13 3229 10.3390/nu13093229 34579110
Asnani A. Moslehi J.J. Adhikari B.B. Baik A.H. Beyer A.M. de Boer R.A. Ghigo A. Grumbach I.M. Jain S. Zhu H. et al. Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement from the American Heart Association Circ. Res. 2021 129 e21 e34 10.1161/RES.0000000000000473 33934611
Lipshultz S.E. Herman E.H. Anthracycline cardiotoxicity: The importance of horizontally integrating pre-clinical and clinical research Cardiovasc. Res. 2018 114 205 209 10.1093/cvr/cvx246 29272330
Pilz P.M. Ward J.E. Chang W.T. Kiss A. Bateh E. Jha A. Fisch S. Podesser B.K. Liao R. Large and Small Animal Models of Heart Failure with Reduced Ejection Fraction Circ. Res. 2022 130 1888 1905 10.1161/CIRCRESAHA.122.320246
Nair A.B. Jacob S. A simple practice guide for dose conversion between animals and human J. Basic Clin. Pharm. 2016 7 27 31 10.4103/0976-0105.177703
Wilcox N.S. Rotz S.J. Mullen M. Song E.J. Ky Hamilton B. Moslehi J. Armenian S.H. Wu J.C. Rhee J.W. Ky B. Sex-Specific Cardiovascular Risks of Cancer and Its Therapies Circ. Res. 2022 130 632 651 10.1161/CIRCRESAHA.121.319901 35175846
Evens L. Belien H. D’Haese S. Haesen S. Verboven M. Rummens J.L. Bronckaers A. Hendrikx M. Deluyker D. Bito V. Combinational Therapy of Cardiac Atrial Appendage Stem Cells and Pyridoxamine: The Road to Cardiac Repair? Int. J. Mol. Sci. 2021 22 9266 10.3390/ijms22179266 34502175
Zacchigna S. Paldino A. Falcao-Pires I. Daskalopoulos E.P. Dal Ferro M. Vodret S. Lesizza P. Cannata A. Miranda-Silva D. Lourenco A.P. et al. Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: A position paper of the ESC Working Group on Myocardial Function Cardiovasc. Res. 2021 117 43 59 10.1093/cvr/cvaa110
Haesen S. Col U. Schurgers W. Evens L. Verboven M. Driesen R.B. Bronckaers A. Lambrichts I. Deluyker D. Bito V. Glycolaldehyde-modified proteins cause adverse functional and structural aortic remodeling leading to cardiac pressure overload Sci. Rep. 2020 10 12220 10.1038/s41598-020-68974-4
Schindelin J. Arganda-Carreras I. Frise E. Kaynig V. Longair M. Pietzsch T. Preibisch S. Rueden C. Saalfeld S. Schmid B. et al. Fiji: An open-source platform for biological-image analysis Nat. Methods 2012 9 676 682 10.1038/nmeth.2019
Deluyker D. Ferferieva V. Noben J.P. Swennen Q. Bronckaers A. Lambrichts I. Rigo J.M. Bito V. Cross-linking versus RAGE: How do high molecular weight advanced glycation products induce cardiac dysfunction? Int. J. Cardiol. 2016 210 100 108 10.1016/j.ijcard.2016.02.095
Derveaux S. Vandesompele J. Hellemans J. How to do successful gene expression analysis using real-time PCR Methods 2010 50 227 230 10.1016/j.ymeth.2009.11.001 19969088
Bustin S.A. Benes V. Garson J.A. Hellemans J. Huggett J. Kubista M. Mueller R. Nolan T. Pfaffl M.W. Shipley G.L. et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments Clin. Chem. 2009 55 611 622 10.1373/clinchem.2008.112797
Celutkiene J. Plymen C.M. Flachskampf F.A. de Boer R.A. Grapsa J. Manka R. Anderson L. Garbi M. Barberis V. Filardi P.P. et al. Innovative imaging methods in heart failure: A shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology Eur. J. Heart Fail. 2018 20 1615 1633 10.1002/ejhf.1330
Chan B.Y.H. Roczkowsky A. Cho W.J. Poirier M. Sergi C. Keschrumrus V. Churko J.M. Granzier H. Schulz R. MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling Cardiovasc. Res. 2021 117 188 200 10.1093/cvr/cvaa017
McLean B.A. Patel V.B. Zhabyeyev P. Chen X. Basu R. Wang F. Shah S. Vanhaesebroeck B. Oudit G.Y. PI3Kalpha Pathway Inhibition with Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling with Right Ventricular Dysfunction J. Am. Heart Assoc. 2019 8 e010961 10.1161/JAHA.118.010961
Garcia-Diez G. Monreal-Corona R. Mora-Diez N. Complexes of Copper and Iron with Pyridoxamine, Ascorbic Acid, and a Model Amadori Compound: Exploring Pyridoxamine’s Secondary Antioxidant Activity Antioxidants 2021 10 208 10.3390/antiox10020208 33535448
El-Agamy D.S. El-Harbi K.M. Khoshhal S. Ahmed N. Elkablawy M.A. Shaaban A.A. Abo-Haded H.M. Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways Cancer Manag. Res. 2019 11 47 61 10.2147/CMAR.S186696
Zhang H. Xu A. Sun X. Yang Y. Zhang L. Bai H. Ben J. Zhu X. Li X. Yang Q. et al. Self-Maintenance of Cardiac Resident Reparative Macrophages Attenuates Doxorubicin-Induced Cardiomyopathy through the SR-A1-c-Myc Axis Circ. Res. 2020 127 610 627 10.1161/CIRCRESAHA.119.316428 32466726
Li D. Liu X. Pi W. Zhang Y. Yu L. Xu C. Sun Z. Jiang J. Fisetin Attenuates Doxorubicin-Induced Cardiomyopathy In Vivo and In Vitro by Inhibiting Ferroptosis Through SIRT1/Nrf2 Signaling Pathway Activation Front. Pharmacol. 2021 12 808480 10.3389/fphar.2021.808480
Ross D. Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics Methods Enzymol. 2004 382 115 144 10.1016/S0076-6879(04)82008-1 15047100
Blanco J.G. Leisenring W.M. Gonzalez-Covarrubias V.M. Kawashima T.I. Davies S.M. Relling M.V. Robison L.L. Sklar C.A. Stovall M. Bhatia S. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer Cancer 2008 112 2789 2795 10.1002/cncr.23534 18457324
Xu X. Persson H.L. Richardson D.R. Molecular pharmacology of the interaction of anthracyclines with iron Mol. Pharmacol. 2005 68 261 271 10.1124/mol.105.013383
Panjrath G.S. Patel V. Valdiviezo C.I. Narula N. Narula J. Jain D. Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model J. Am. Coll. Cardiol. 2007 49 2457 2464 10.1016/j.jacc.2007.02.060
Huo M. Tang Z. Wang L. Zhang L. Guo H. Chen Y. Gu P. Shi J. Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron Nat. Commun. 2022 13 7778 10.1038/s41467-022-35503-y
Fang X. Wang H. Han D. Xie E. Yang X. Wei J. Gu S. Gao F. Zhu N. Yin X. et al. Ferroptosis as a target for protection against cardiomyopathy Proc. Natl. Acad. Sci. USA 2019 116 2672 2680 10.1073/pnas.1821022116
Tadokoro T. Ikeda M. Ide T. Deguchi H. Ikeda S. Okabe K. Ishikita A. Matsushima S. Koumura T. Yamada K.I. et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity JCI Insight 2020 5 e132747 10.1172/jci.insight.132747
Chen X. Comish P.B. Tang D. Kang R. Characteristics and Biomarkers of Ferroptosis Front. Cell Dev. Biol. 2021 9 637162 10.3389/fcell.2021.637162 33553189
Williams M.E. Bolton W.K. Khalifah R.G. Degenhardt T.P. Schotzinger R.J. McGill J.B. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy Am. J. Nephrol. 2007 27 605 614 10.1159/000108104 17823506
Dwyer J.P. Greco B.A. Umanath K. Packham D. Fox J.W. Peterson R. Broome B.R. Greene L.E. Sika M. Lewis J.B. Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): Lessons learned from a pilot study Nephron 2015 129 22 28 10.1159/000369310 25532068
Haesen S. Verghote E. Heeren E. Wolfs E. Deluyker D. Bito V. Pyridoxamine attenuates doxorubicin-induced cardiomyopathy without affecting its antitumor effect on rat mammary tumor cells Cells 2024 13 120 10.3390/cells13020120
